Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Derek W Nelson

William A Carroll

Arturo Perez-Medrano

Sridhar Peddi

Tongmei Li

Michael J Dart

Teodozyj Kolasa

Meena V Patel

Jennifer M Frost

Xueqing Wang

Bo Liu

Alan S Florjancic

Steven P Latshaw

Karin Rosemarie Tietje

Keith Brian Ryther

Eric M Bunnelle

Megan E Gallagher

Gavin C Hirst

Michael E Kort

Tammie K Jinkerson

Marlon D Cowart

David A DeGoey

John R Koenig

Marc J Scanio

Andrew Bogdan

Mark A Matulenko

Biqin C Li

Brian D Wakefield

Hillary M Peltier

Philip R Kym

Arthur Gomtsyan

Gregory A Gfesser

Jerome F Daanen

Kevin R Woller

Eric A Voight

Ryan G Keddy

Anurupa Shrestha

Biquin C Li

Gavin C H Hirst

Bigin Li

Keith B Ryther

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

The present invention relates compounds of formula (I) wherein A and Rare as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.

Compounds as cannabinoid receptor ligands

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and L, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

Compounds as cannabinoid receptor ligands and uses thereof

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein L, A, R, z, R, R, and Rare as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A, A, R, X, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and Lare defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R, R, R, R, and L are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

The present invention relates to thiophene containing compounds of formula (I) wherein m, n, p, q, r, s, R, R, and Rare as defined in the description. Included also are pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions.

Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands

A compound having Formula (I) or Formula (II) 

Amino-tetrazoles analogues and methods of use

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and Lare defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, 

The present invention provides for compounds of formula (I) wherein A, L, R, R, R, R, R, R, q1, and z are as defined in the specification, are prodrugs of CBreceptors ligands and as such are useful in the prevention and treatment of various diseases and conditions including, but not limited to, pain.

Prodrug compounds useful as cannabinoid ligands

The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R, R, R, R, and L are as defined in the specification, compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.

Disclosed herein are compounds of formula (I) wherein Ring A and Rare as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.

Growing community of inventors

Highland Park, IL, United States of America

Derek W Nelson